AstraZeneca
NEWS
Emulate, Inc. struck a deal with pharma giant AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit to embed its Organs-on-Chips technology within the laboratories of the IMED Drug Safety organization.
AstraZeneca and its biologics research-and-development arm, MedImmune, indicated that its Fasenra (benralizumab) did not meet its primary endpoint in patients with moderate to very severe COPD.
Changes continue at the c-suite level of GlaxoSmithKline. This week another high profile executive, Chief Financial Officer Simon Dingemans announced he will retire from GSK in 2019.
Some accelerators come out of government and academic institutions, while others have specific big pharma backing. Many use a combination of all of the above, while some are private in nature linked to venture capital firms. Let’s look at some of the accelerators linked to big pharma.
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
The U.S. Food and Drug Administration (FDA) granted Genentech’s Tecentriq triple combination with Avastain (bevacizumab), paclitaxel and carboplatin (chemotherapy) Priority Review for first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
Biopharmaceutical companies are focusing their drugs for smaller and smaller and more clearly delineated patient populations. No longer is a drug for lung cancer or even non-small cell lung cancer, but a much smaller segment.
Regeneron and its longtime development partner Sanofi are keeping their proverbial fingers crossed that their profitable collaboration will yield yet another approved treatment this year.
Corvidia Therapeutics, headquartered in Waltham, Massachusetts, closed on a Series B funding round worth $60 million.
JOBS
IN THE PRESS